ChemicalBook >> CAS DataBase List >>N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide structure

CAS No.: 875337-44-3

Chemical Name:: N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide

Synonyms: CS-31;MGCD-265;MGCG-265;MGCD-265 analog;MGCD 265; MGCD265;MGCD-265 (Glesatinib);MGCD-265 (Synonyms MGCD265);MGCD265-analog. Glesatinib-analog.;MGCD-265-ANALOG; MGCD 265-ANALOG; MGCD265-ANALOG. GLESATINIB-ANALOG.;N-(3-Fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbAmothioyl)-

CBNumber:: CB72515097

Molecular Formula:: C26H20FN5O2S2

Molecular Weight:: 517.6

MDL Number:: MFCD17779287

MOL File:: 875337-44-3.mol

MSDS File:: SDS

Last updated:2023-09-20 16:43:00

Request For Quotation

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide Properties

Density	1.41
storage temp.	Store at -20°C
solubility	≥25.9 mg/mL in DMSO; insoluble in EtOH; insoluble in H2O
form	solid
pka	10.07±0.70(Predicted)
FDA UNII	93M6577H9D

SAFETY

Risk and Safety Statements

Symbol(GHS)

GHS07

Signal word

Warning

Hazard statements

H302-H332-H312

Precautionary statements

P261-P271-P304+P340-P312-P280-P302+P352-P312-P322-P363-P501-P264-P270-P301+P312-P330-P501

NFPA 704

	0
3		0

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide price More Price(32)

Manufacturer	Product number	Product description	CAS number	Packaging	Price	Updated	Buy
Cayman Chemical	20097	MGCD-265 ≥98%	875337-44-3	1mg	$43	2024-03-01	Buy
Cayman Chemical	20097	MGCD-265 ≥98%	875337-44-3	5mg	$172	2024-03-01	Buy
Cayman Chemical	20097	MGCD-265 ≥98%	875337-44-3	10mg	$322	2024-03-01	Buy
Cayman Chemical	20097	MGCD-265 ≥98%	875337-44-3	50mg	$1125	2023-06-20	Buy
TRC	M198700	MGCD-265	875337-44-3	50mg	$1025	2021-12-16	Buy

Product number	Packaging	Price	Buy
20097	1mg	$43	Buy
20097	5mg	$172	Buy
20097	10mg	$322	Buy
20097	50mg	$1125	Buy
M198700	50mg	$1025	Buy

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide Chemical Properties,Uses,Production

Uses

MGCD-265 is a novel dual c-Met/ VEGFR2 receptor tyrosine kinase inhibitor possessing favorable pharmacokinetic profiles and showed high efficacy in vivo in several human tumor xenograft models in mice.

Uses

MGCD-265 is a multi-targeted kinase inhibitor, which targets the c-MET, VEGFR1, VEGFR2, VEGFR3, Tie-2 and Ron receptor tyrosine kinases.

Uses

Definition

ChEBI: N-[[3-fluoro-4-[[2-(1-methyl-4-imidazolyl)-7-thieno[3,2-b]pyridinyl]oxy]anilino]-sulfanylidenemethyl]-2-phenylacetamide is a member of thioureas.

Biological Activity

mgcd-265 is a multi-target and atp-competitive inhibitor of c-met and vegfr1, 2, 3 with ic50 values of 1 nm, 3 nm, 3 nm and 4 nm, respectively. [1]in non-small cell lung cancer xenograft models including one that harbored the tki resistant egfr mutation t790m, mgcd265 combined with either paclitaxel, docetaxel or erlotinib. each combination elicited greater tumor response than agent alone, and displayed antiangiogenic properties with docetaxel [2].mgcd265 has been studied in a variety of advanced solid tumors including nsclc, as a monotherapy and in combination with either docetaxel or erlotinib. in a phase i study, mgcd265 was given orally from 24 mg/m2 daily to 235 mg/m2 twice daily uninterrupted to patients with advanced solid malignancy until disease progression [3]. in a phase i standard 3+3 dose escalation, mgcd265 (96 mg/m2 once daily up to 162 mg/m2 bid) was combined with erlotinib at 100 or 150 mg daily to determine safety, and 45 patients have been enrolled. in a separate phase i dose escalating trial, mgcd265 was combined with docetaxel (50 then 75 mg/m2 iv once every 3 weeks) in advanced solid tumors (n=34), including 9 nsclc patients. the mtd of the microionized formulation of mgcd265 is 72 mg/m2 bid and docetaxel 75 mg/m2 every 3 weeks but has not been reached with the new formulation. [4][5]

target

c-Met

References

[1] bonfils c. et al. aacr 2012 annual meeting, 2012. abstract 1790.
[2]. besterman jm, fournel m, dupont i, et al. potent preclinical antitumor activity of mgcd265, an oral met/vegfr kinase inhibitor in phase ii clinical development, in combination with taxanes or erlotinib. j clin oncol 2010;28:abstr e13595.
[3]. kollmannsberger ck, hurwitz h, vlahovic g, et al. phase i study of daily administration of mgcd265 to patients with advanced malignancies (study 265-101). j clin oncol 2009;27:abstr e14525.
[4]. kollmannsberger ck, hurwitz h, cleary jm, et al. mgcd265, a multitargeted oral tyrosine kinase receptor inhibitor of met and vegfr: dose-escalation phase i study (abstr 3039). 2012 asco annual meeting chicago, il. j clin oncol 2012;30:abstr 3039.
[5]. drouin ma, kollmannsberger ck, uronis he, et al. daily administration of mgcd265 to patients with solid tumors in a dose-escalation phase i study (study 265-101). j clin oncol 2010;28:abstr 3106.

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide Preparation Products And Raw materials

Raw materials

Preparation Products

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide Suppliers

Global( 114)Suppliers

Supplier	Tel	Email	Country	ProdList	Advantage
ATK CHEMICAL COMPANY LIMITED	+undefined-21-51877795	ivan@atkchemical.com	China	32480	60
career henan chemical co	+86-0371-86658258	sales@coreychem.com	China	29914	58
Hubei Jusheng Technology Co.,Ltd.	18871490254	linda@hubeijusheng.com	CHINA	28180	58
Chongqing Chemdad Co., Ltd	+86-023-61398051 +8613650506873	sales@chemdad.com	China	39916	58
Alchem Pharmtech,Inc.	8485655694	sales@alchempharmtech.com	United States	63711	58
CONIER CHEM AND PHARMA LIMITED	+8618523575427	sales@conier.com	China	47465	58
Dideu Industries Group Limited	+86-29-89586680 +86-15129568250	1026@dideu.com	China	29271	58
Dayang Chem (Hangzhou) Co.,Ltd.	571-88938639 +8617705817739	info@dycnchem.com	CHINA	52867	58
Zhejiang J&C Biological Technology Co.,Limited	+1-2135480471 +1-2135480471	sales@sarms4muscle.com	China	10523	58
InvivoChem	+1-708-310-1919 +1-13798911105	sales@invivochem.cn	United States	6393	58

Supplier	Advantage
ATK CHEMICAL COMPANY LIMITED	60
career henan chemical co	58
Hubei Jusheng Technology Co.,Ltd.	58
Chongqing Chemdad Co., Ltd	58
Alchem Pharmtech,Inc.	58
CONIER CHEM AND PHARMA LIMITED	58
Dideu Industries Group Limited	58
Dayang Chem (Hangzhou) Co.,Ltd.	58
Zhejiang J&C Biological Technology Co.,Limited	58
InvivoChem	58

View Lastest Price from N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide manufacturers

Image	Update time	Product	Price	Min. Order	Purity	Supply Ability	Manufacturer
	2019-07-06	N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide 875337-44-3	US $2.00 / kg	1kg	99%	100kg	Career Henan Chemical Co

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide
875337-44-3
US $2.00 / kg
99%
Career Henan Chemical Co

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide Spectrum

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide(875337-44-3)¹HNMR

875337-44-3(N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide)Related Search:

N-Methylbenzylamine 2-Methylaminoethanol N-Methyl pyrrole N-Methylbenzamide N-Methyldiethanolamine

Sotrastaurin Enzastaurin (LY317615) Selumetinib Cabozantinib PD 0332991 HCl

Veliparib

1of3

N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide MGCD-265 (Synonyms MGCD265) MGCD-265 N-(3-fluoro-4-(2-(1-Methyl-1H-iMidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbaMothioyl)-2-phen N-[[[3-fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]-benzeneacetamide N-(3-Fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide MGCD-265 MGCD-265 analog N-(3-Fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbAmothioyl)- MGCD265-analog. Glesatinib-analog. MGCD-265-ANALOG; MGCD 265-ANALOG; MGCD265-ANALOG. GLESATINIB-ANALOG. MGCD-265 (Glesatinib) CS-31 MGCD 265; MGCD265 Benzeneacetamide, N-[[[3-fluoro-4-[[2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yl]oxy]phenyl]amino]thioxomethyl]- N-(3-fluoro-4-(2-(1-methyl-1H-imidazol-4-yl)thieno[3,2-b]pyridin-7-yloxy)phenylcarbamothioyl)-2-phenylacetamide USP/EP/BP MGCG-265 875337-44-3 C26H20FN5O2S2 Inhibitors